Cristin Rothfuss
Known title: EVP, General CounselCIK: 0002046214
Associated companies
Transaction History
| SRPT | ▼ Sell | Tax Withholding | 22,025 | $489K | 9/4/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 974 | $17K | 3/11/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 484 | $8K | 3/9/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 346 | $6K | 3/9/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 408 | $7K | 3/2/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 229 | $5K | 11/28/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 25,000 | $0 | 9/3/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 93,875 | $0 | 9/3/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 491 | $49K | 3/10/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 8,276 | — | 3/10/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,131 | $117K | 3/7/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 347 | $36K | 3/7/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 296 | $30K | 3/4/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 288 | $29K | 3/4/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 391 | $41K | 3/3/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 2,000 | $0 | 11/26/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M
Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.